natgillin/translations-raw huggingface dataset:
the first fragment is a toxin A repeating domain fragment; 
() prvi fragment je fragment ponavljajuće domene toksina A 1z bakterije C. difficile;
The therapeutic activity of the composition becomes more favourable and the likelihood of the occurrence of side-effects considerably decreases. 
Terapijska aktivnost smjese postaje bolja i vjerojatnost pojave sporednih učinaka značajno se smanjuje.
Polycarboxylic acid metal salts are preferred. Advantageously, the carboxylic acid metal salt is a metal salt of a branched or unbranched, saturated or unsaturated, alicyclic acid, of a cyclic acid or of an aromatic acid. 
Proizvod sukladno zahtjevima 1 do 3, naznačen time da je metalna sol polikarboksilne kiseline metalna sol dikarboksilne, trikarboksilne ili tetrakarboksilne nepolimerske kiseline koja je aliciklička, razgranata ili ne, zasićena ili nezasićena, ciklička ili aromatska.
is methyl; or a salt thereof. Fixed combination, non-fixed combination or kit of parts comprising at least one of the compounds or stereoisomers of the compounds according to any of claims 1 to 8, at least one therapeutic agent selected from the group consisting of corticosteroids, anticholinergics, B2-adrenoceptor agonists, H1 receptor antagonists, leukotriene receptor antagonists, type 5 phosphodiesterase inhibitors, HMG-CoA reductase inhibitors, lung surfactants and antibiotics, and at least one pharmaceutically acceptable auxiliary. 
Fiksirana kombinacija, nefiksirana kombinacija ili garnitura od segmenata, naznačena time, da obuhvaća barem jedan od spojeva ili stereoizomera spojeva prema bilo kojem od zahtjeva 1 do 8, barem jedno terapeutsko sredstvo odabrano iz skupine koju čine kortikosteroidi, antikolinergici, agonisti B2-adrenoceptora, antagonisti H1 receptora, antagonisti leukotrien receptora, inhibitori fosfodiesteraze tipa 5, inhibitori HMG-CoA reduktaze, plućni surfaktanti i antibiotici, te barem jedno farmaceutski prihvatljivo pomoćno sredstvo.
The C-terminal OspA fragment of the current invention may also include a lipidation signal sequence at the N-terminus, e.g., the lipidation signal sequence of amino acids 1 to 16 of OspA (SEQ ID NO: 13) or OspB (SEQ ID NO: 14) from B. burgdorferi s.s. strain B31, a lipidation signal sequence from E. coli, referred to herein as the “lpp lipidation signal” (SEQ ID NO: 15), or any other signal sequence, e.g., as defined below. 
Polipeptid sukladno patentnom zahtjevu I ili 2 i) gdje je polipeptid lipidiran ili gdje polipeptid sadrži signal za lipidaciju, poželjno £. coli derivirane Ipp lipidacije signal MKATKLVLGAVILGSTLLAG (SEQ ID NO: 15); i /ili ii) - gdje polipeptid obuhvaća peptid na mjestu lipidacije koji je voden s N-terminalnim cisteinskim ostatkom kao mjestom za lipidaciju, poželjno CSS; i / ili ili) "gdje polipeptid sadrži vezu između hibridnog C-terminalnog OspA fragmenta i drugog C-terminalni OspA fragmenta, posebno gdje navedena veza sadrži GTSDKNNGSGSKEKNKDGKYS (SEQ ID br. 16).
A pharmaceutical composition comprising an antibody according to any one of claims 1-18 or 22-30 and/or a conjugate of claim 31, and a pharmaceutically acceptable carrier. 
Farmaceutski sastav obuhvaća protutijelo iz bilo kojeg od patentnih zahtjeva 1 do 5 i/ili konjugat iz patentnog zahtjeva 7 i farmaceutski prihvatljivi nosač.
The method of claim 1 further comprising the step of generating one of a magnetic dipole field and a magnetic quadrupole field within the chamber with saddle coils coupled to the chamber. 
generiranje jednog od magnetskog dvopolnog polja i magnetskog četveropolnog polja unutar komore sa sedlastim zavojnicama (460) koje su spojene s komorom;
PCT and European Patent Application are claimed. 
31.07.2013. Broj europske prijave patenta:
6 shows a cross sectional view in the extraction module according to the present invention in its open state. 
Slika 6 prikazuje pogled na poprečni presjek modula za ekstrakciju koji je u skladu s predmetnim izumom kada je ovaj u svojem otvorenom položaju.
The method according to claim 23, wherein before the step of adding the Grignard reagent of the formula IX to the thiolactone of the formula VIII to obtain a compound V, about 0.8 to 1.2 equivalents of R30MgX (R30 represents a C1-8 alkyl group or a C3-7 cycloalkyl group, and X represents a halogen atom) is added to the thiolactone of the formula VIII. 
Postupak prema zahtjevu 26, naznačen time da se prije koraka dodavanja Grignardovog reagensa formule IX u tiolakton formule VIII da se dobije spoj V, oko 0.8 do 1.2 ekvivalenata R30MgX (R30 predstavlja C1-8 alkil skupinu ili C3-7 cikloalkil skupinu, te X predstavlja atom halogena) dodaje u tiolakton formule VIII.
a human CMV (HCMV) vector that encodes a heterologous antigen and functional US2-US6 proteins and does not express an active US11 protein, or 
(a) ljudski vektor CMV (HCMV), koji kodira heterologni antigen i funkcionalne proteine US2-US6, a ne eksprimira aktivni protein US11, ili
The method of claim 5, wherein the inhibitor of NS5B polymerase is a non-nucleoside inhibitor. 
Farmaceutski sastav koji se sastoji iz spoja iz patentnog zahtjeva 2 i inhibitora NS5B polimeraze.
Figure 2. Comparative stability study. 
Slika 2. = Usporedno ispitivanje stabilnosti.
Apparatus as in claim 2, wherein during said backwashing process said permeate is fed into said cavity (9) and flows into said ducts passing through the filtering surfaces of said filtering membranes (7). 
Uređaj prema zahtjevu 2, naznačen time da se tijekom navedenog postupka ispiranja navedeni permeat uvodi u navedenu šupljinu (9) 1 utječe u navedene kanale koji prolaze kroz filtracijske površine navedenih filtracijskih membrana (7).
A hCCR2 KI mouse study was conducted to evaluate the effect of Example I on monocyte/macrophage infiltration in thioglycollate (TG) peritonitis model with cell differential counting-based and flow cytometry-based methodologies. 
SLIKA 14 48-satni tioglikolatni (TG) model peritonitisa u hCCR2 K1 miševa: Primjer 1 inhibicija infiltracije monocita/makrofaga u peritonealnu šupljinu (diferencijalni broj stanica) Ukupni leukociti .
detecting with the processor mechanism at least a third user marking cell on the form, wherein the third user marking cell is bounded by an indicium that is visible to the camera, and wherein the third user marking cell is detected based at least in part upon at least one of: (a) a position of the detected first user marking cell; and (b) a position of the detected second user marking cell. The method of claim 6, further comprising: 
detektiranje procesorskim mehanizmom u najmanju ruku treće ćelije za korisničku oznaku na formularu (400, 700), gdje je treća ćelija za korisničku oznaku omeđena bilješkom vidljivom za kameru, te gdje se treću ćeliju za korisničku oznaku detektira na temelju u najmanju ruku dijelom najmanje jednog od: (a) položaja detektirane prve ćelije za korisničku oznaku; i (b) položaja detektirane druge ćelije za korisničku oznaku.
The composition of claim 9 wherein said pH adjusting agent is sodium bicarbonate, sodium carbonate, sodium hydroxide, potassium hydroxide, calcium hydroxide, tromethamine (Tris), or mixtures thereof, preferably sodium bicarbonate, tromethamine (Tris), or mixtures thereof. 
Sastav prema zahtjevu 9, naznačeno time da je spomenuti agens prilagodbe pH vrijednosti natrijev bikarbonat, natrijev karbonat, natrijev hidroksid, kalijev hidroksid, kalcijev hidroksid, trometamin (Tris), ili mješavina istih, poželjno natrijev bikarbonat, trometamin (Tris) ili mješavina istih.
The pharmaceutical compositions of this invention, or those which are manufactured in accordance with this invention, may be administered by any suitable route, for example orally in the form of tablets, capsules, powders, syrups, etc., or parenterally in the form of solutions for injection. 
Farmaceutski sastavi ovog izuma, ili sastavi koji su proizvedeni u skladu s ovim izumom, mogu se davati na bilo koji prikladan način, na primjer oralno u obliku tableta, kapsula, prašaka, sirupa itd., ili parenteralno u obliku otopina za injekcije.
Use of the method according to one of claims 1-4 for controlling the distribution of food to zooplankton in an automated copepod egg production facility. 
Uporaba postupka prema jednom od zahtjeva 1-4 naznačena time da je za kontrolu raspodjele hrane za zooplankton u automatiziranom pogonu za proizvodnju jaja kopepoda.
For administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of a dry powder inhaler, or an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. 
Kod primjene inhalacijom spojevi namijenjeni upotrebi prema ovom izumu pogodno se unaša putem inhalatora sa suhim prahom, ili ih se prezentira kao aerosolni sprej iz paketa pod tlakom ili nebulizatora, uz upotrebu pogodnog pogonskog plina, primjerice diklordifluormetana, triklorfluormetana, diklortetrafluoretana, ugljičnog dioksida ili kojeg drugog pogodnog plina.
The system as claimed in claim 7 wherein a first tip of the first electrode is planar and a second tip of the second electrode is planar. 
Sustav prema zahtjevu 7, pri čemu su prvi vrh prve elektrode (2b.1) i drugi vrh druge elektrode (2b.2) ravni.
the main species HER2 antibody comprising a C-terminal lysine residue on two heavy chains thereof, 
glavni rod HER2-protutijela koji sadrže C-završni ostatak lizina na dva njegova jaka lanca,
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) fenpropimorph. 
Spoj prema zahtjevu 1, naznačen time, da sadrži kao komponentu (A) spoj (9-difluorometiliden-benzonorbornen-5ilamid 3-difluorometil-1-metil-1H-pirazol-4-karboksilne kiseline, te kao komponentu (B) mandipropamid.
the racemisation promoter is selected from the group consisting of 5-nitrosalicylic aldehyde, 3,5-dichlorosalicylic aldehyde, 2-nitro benzaldehyde, 4-nitrobenzaldehyde, 2,4-dinitrobenzaldehyde, salicylic aldehyde and pyridoxal-5'-phosphate; and/or the racemisation promoter is present at 2 to 20 mol% relative to the compound of formula II. 
promotor racemizacije je izabran iz grupe koja obuhvaća 5-nitrosalicil aldehid, 3,5-dihlorosalicil aldehid, 2-nitro benzaldehid, 4-nitrobenzaldehid, 2,4-dinitrobenzaldehid, salicil aldehid i piridoksal-5’-fosfat; i/ili promotor racemizacije je prisutan u 2 do 20 mol% u odnosu na spoj formule II.
The temperature of drying was raised to 30-35 °C when the LOD was 5.1 %. 
Temperatura sušenja podignuta je na 30-35 *C kada je LOD bio 5,1 %.
a heavy chain variable region CDR1 of SEQ ID NO: 11; a heavy chain variable region CDR2 of SEQ ID NO: 25; a heavy chain variable region CDR3 of SEQ ID NO: 39; a light chain variable region CDR1 of SEQ ID NO: 53; a light chain variable region CDR2 of SEQ ID NO: 67; and a light chain variable region CDR3 of SEQ ID NO: 81, 
(k) CDRI varijabilnog područja jakog lanca sa SEQ ID NO: 11; CDR2 varijabilnog područja jakog lanca sa SEQ ID NO: 25; CDR3 varijabilnog područja jakog lanca sa SEQ ID NO: 39; CDRI varijabilnog područja slabog lanca sa SEQ ID NO: 53; CDR2 varijabilnog područja slabog lanca sa SEQ ID NO: 67; 1 CDR3 varijabilnog područja slabog lanca sa SEQ ID NO: 81;
* (number of asymmetric units in the unit cell) 
(97) Broj objave europskog patenta:
a therapeutically effective amount of any one of the compounds of claims 1-15 for use in treating cancer in a subject, wherein optionally the cancer is breast cancer. 
Terapijski učinkovita količina bilo kojeg od spojeva prema zahtjevima 1-21 za uporabu u liječenju raka u subjekta.
The pharmaceutical composition of any one of claims 3-6, wherein the pharmaceutical composition has a pH of about 4. 
Farmaceutska kompozicija bilo kojeg od patentnih zahtjeva 3-6, gdje farmaceutska kompozicija ima pH od oko 4.
an alkyl or cycloalkyl group of 3 to 6 carbon atoms, linear or branched, optionally substituted by one or more halogen atoms or by one or more groups cycloalkyl, hydroxy, C1-C8 alkoxy, amino, mono- or di-C1-C8 alkylamino 
alkilnu ili cikloalkilnu skupinu od 3-6 ugljikovih atoma, linearnu ili razgranatu, opcionalno supstituiranu s jednim ili više halogenih atoma ili s jednom ili više cikloalkilnih, hidroksi, C1-C8 alkoksi, amino, mono- ili di-C1-C8 alkilamino skupina
The non-nucleophilic base may be triethylamine. 
Postupak iz patentnog zahtjeva 4, u kome je ne-nukleofilna baza trietilamin.
Hydrolysis of Peak 1 to give Isomer A 
Hidroliza Peak-a 1 da bi se dobio Izomer A
represents the side chain of the amino acid residue Ser and Thr; 
R, predstavlja pobočni lanac aminokiselinskog ostatka Ser i Thr;
The prodrug of any of claims 1 to 14 or the pharmaceutical composition of claim 15 for use in a method of treating or preventing diseases or disorders which can be treated by exendin. 
Predlijek prema bilo kojem od zahtjeva 1 do 12 ili farmaceutski pripravak prema patentnom zahtjevu 15 naznačen time što je za uporabu u postupku liječenja ili sprječavanja bolesti ili poremećaja koji se mogu liječiti eksendinom.
The oral dosage form according to any one of the preceding features wherein the enteric coating provides for release of the bisphosphonate and the EDTA in the large intestine. 
Oralni oblik za doziranje prema zahtjevu 1 ili zahtjevu 2, naznačen time da oralni oblik za doziranje omogućuje oslobađanje bisfosfonata i EDTA kao bolus u nižem gastrointestinalnom traktu, poželjno u debelom crijevu.
The method of claim 2, wherein the pulmonary disease or disorder is selected from at least one of asthma, chronic obstructive pulmonary disease allergic rhinitis, sinusitis, pulmonary vasoconstriction, inflammation, allergies, impeded respiration, respiratory distress syndrome, pulmonary hypertension, pulmonary inflammation associated with cystic fibrosis, and pulmonary obstruction associated with cystic fibrosis. 
Ko-suspenzija namijenjena upotrebi u skladu s patentnim zahtjevom 20, naznačena time što se plućna bolest ili poremećaj bira između najmanje jednog od astme, COPD, pogoršanja preosjetljivosti dišnih puteva kao posljedice terapije drugim lijekom, alergijskog rinitisa, sinusitisa, plućne vazokonstrikcije, upale, alergija, otežanog disanja, respiratornog distresnog sindroma, plućne hipertenzije, te upale pluća i opstrukcije povezane s cističnom fibrozom.
Mill (20) according to any one of Claims 4 or 5, wherein the side wall (24) is shaped so as to follow precisely the profile of the grinding volumes (28). 
Mlin (20) sukladno bilo kojem od zahtjeva 4 ili 5, pri čemu je bočni zid (24) oblikovan tako da precizno prati profil volumena za mljevenje (28).
The method of claim 1, wherein the aluminum oxyhydroxide is administered to the AD patient subcutaneously, intranodally, intradermally, or intramuscularly. 
Aluminijev oksihidroksid za uporabu prema bilo kojem od zahtjeva 1 do 7, naznačen time, da se aluminijev oksihidroksid primjenjuje na AD-pacijentu subkutano, intranodalno, intradermalno, ili intramuskularno, posebice subkutano.
The strips of fabric 16 of the first layer 11 have a width of no less than 2 millimeters and no more than 6 millimeters and preferably a width of approximately 4 millimeters. 
Tkanina u skladu s jednim ili više prethodnih patentnih zahtjeva, naznačena time, da navedene trake tkanine (16) prvog sloja (11) imaju širinu od najmanje 2 mm i ne više od 6 mm, poželjno širinu od oko 4 mm.
Objectcomprising a stretched polyolefin material, which object has an E-modulus of at least 5.5 GPa, preferably at least 7 GPa, more preferably at least 8 GPa, as measured by ISO 527-4; and a tensile strength of at least 200 MPa, preferably at least 250 MPa, as measured by ISO 527-4. 
Predmet koji obuhvaća rastegnuti poliolefinski materijal, naznačen time, da taj predmet ima E-modul od najmanje 5,5 GPa, poželjno najmanje 7 GPa, najbolje od najmanje 8 GPa, mjereno prema ISO 527-4: te čvrstoću na rastezanje od najmanje 200 MPa, poželjno od najmanje 250 MPa, mjereno prema ISO 527-4.
The compound according to claim 1 wherein K is N and L and M are each C. 
Spoj u skladu s patentnim zahtjevom 1, gdje K je N, asvaki od LiM je C.
A compound that has the structure of Formula (XII): wherein, X1 is CH, CR3 or N; 
Spoj koji ima strukturu prema Formuli (XII):
a pyridine carboxylic acid herbicide, wherein the pyridine carboxylic acid herbicide includes 4-amino-3-chloro-5-fluoro-6-(7-fluoro-1H-indol-6-yl) picolinic acid, or an agriculturally acceptable N-oxide, salt, or ester thereof; and 
herbicid na bazi piridinkarboksilne kiseline, gdje herbicid na bazi piridinkarboksilne kiseline sadrži 4-amino-3-klor-5-fluor-6-(7-fluor-1H-indol-6-il)pikolinsku kiselinu, ili njezin poljoprivredno prihvatljivi N-oksid, sol ili ester; i
The composition or vaccine of any one of claims 1-3 for use in a method of vaccinating an animal, said method comprising at least one administration of the composition or vaccine. 
Sastav ili cjepivo za uporabu prema bilo kojem od zahtjeva 1-6, naznačen/o time, da rekombinantni vektor Gallid herpesvirusa-3 obuhvaća promotor.
attenuates or completely neutralizes the ability of PD-1 to mediate signal transduction; 
(B) smanjuje ili potpuno neutralizira sposobnost PD-1 da posreduje u prijenosu signala;
Descriptions of these techniques, the synthesis of radiolabeled ligand, the employment of radiolabeled ligand in radioimmunoassay, and the measurement of the effectiveness of a compound as a GnRH receptor antagonist follow. 
Niže su iznijeti opisi tih tehnika, sinteze radioaktivno obilježenog liganda, upotrebe radioaktivno obilježenog liganda u radioimunoispitivanju, te mjerenja djelotvornosti spoja kao antagonista receptora GnRH.
An antisense morpholino oligomer which causes skipping of the 53rd exon in the human dystrophin gene, wherein said oligomer has a nucleotide sequence complementary to the 36th to 53rd nucleotides from the 5' end of exon 53 of human dystrophin gene, and a length of 18 to 28 base pairs. 
Antisensni oligomer koji uzrokuje preskakanje 53. egzona u humanom distrofinskom genu, koji se sastoji od nukleotidne sekvence komplementarne nukleotidima 36. do 60. od 5' kraja 53. egzona humanog distrofinskog gena.
Embodiment No. 4 In yet another embodiment of the present invention the process described in embodiments no. 2 and 3 further incorporate a buffering agent selected from a group comprising Di Sodium Hydrogen Ortho Phosphate, Sodium Hydrogen Ortho Phosphate and the like from about 0.01% (w/w) to 1.00% (w/w), preferably 0.5% (w/w), more preferably 0.05% (w/w). 
Postupak za proizvodnju kreme s fusidinskom kiselinom prema bilo kojem od patentnih zahtjeva 2, 4 1 5, naznačen time, da se nadalje puferski agens dodaje u stupnju a patentnog zahtjeva 2 do 4, kod čega se navedeni puferski agens odabire iz skupine koja sadrži dinatrijev hidrogenortofosfat, natrijev hidrogenortofosfat 1 slične, u količini od oko 0,001% (tež.) do 1,00% (tež.), prvenstveno 0,05% (tež.), pogodnije 0,5% (tež.).
A delta-like ligand 4 (DII4) antagonist for use in preventing, treating or ameliorating diabetes mellitus type 1 in a subject, wherein the antagonist blocks an interaction between DII4 and Notch receptor and diabetes is prevented, treated or ameliorated, and wherein the DII4 antagonist is an antibody or fragment thereof that specifically binds hDII4 and blocks DII4-Notch signal pathways, or a fusion protein comprising the extracellular domain of DII4 that is fused to the Fc domain of a human IgG. 
Antagonist liganda sličnog delti 4 (DII4) za primjenu u sprječavanju, liječenju ili olakšavanju dijabetesa melitusa tip 1 u bolesnika, naznačen time, što antagonist blokira interakciju između DII4 1 Noteh receptora, što sprječava, liječi ili olakšava dijabetes i naznačen time, što je antagonist DII4 antitijelo 1li njegov fragment koji konkretno vezuje hDII4 1 blokira DIl4-Notch signalne puteve, ili fuzijski protein koji se sastoji od izvanstanične domene DII4 koja je spojena s Fc domenom humanog IgG-a.
The antibody or antigen binding fragment thereof, or the antibody drug conjugate for use of claim 13, wherein the cancer is bladder cancer. 
Konjugat antitijela i lijeka za uporabu prema patentnom zahtjevu 20, gdje je rak rak mjehura.
at two successive stations along said conveying line for said containers; in a same station along said conveying line for said containers. 
dvije postaje, duž navedene transportne linije za navedene staklene cijevi ili spremnike izrađene od staklenih cijevi; jedne postaje, duž navedene transportne linije za navedene staklene cijevi ili spremnike izrađene od staklenih cijevi.
The reaction was stirred for 18 h at which time NaHCO3 (sat. aq., 6 mL) was added to quench excess thionyl chloride. 
Reakcija je miješana tijekom 18 sati nakon čega je dodan NaHCO; (zas. aq. 6 mL) da se poništi višak tionil klorida.
a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to a polynucleotide sequence encoding the heavy chain variable domain sequence of H5; 
slijed aminokiselina kodiran polinukleotidnim slijedom koji je najmanje 80% identičan slijedu SEQ ID NO:360;
The tablet as claimed in claim 9, wherein said tablet has a hardness value within the range of about 28-39 SCUs. 
Tableta kao što je zahtijevano u patentnom zahtjevu 9, pri čemu navedena tableta ima vrijednost čvrstine unutar opsega od oko 28-39 SCUs.
Accordingly, in a first aspect, the invention provides 3,11b- cis- dihydrotetrabenazine for use in halting or slowing the progress of one or more symptoms of Huntington's disease selected from involuntary movements and degeneration in gait. 
Prema tome, u prvom aspektu, izum osigurava spoj za uporabu u zaustavljanju ili usporavanju napretka jednog ili više simptoma Huntington-ove bolesti kod pacijenta gdje su simptomi izabrani između nenamjernih pokreta i pogoršanja hoda, pri čemu je spoj (+) izomer 3,1 1b-cis-dihidrotetrabenazina ili njegova farmaceutski prihvatljiva sol.
The method of paragraph 25 wherein the inflammatory, thrombotic condition or other condition or disorder is related to at least one or more of platelet, sickled red cell, leukocyte, lymphocyte or endothelial cell adhesion, vasoocculsive sickle cell pain crisis, thrombosis, atherosclerosis, tumor metastasis, allergic reactions, thyroiditis, psoriasis, dermatitis, nephritis, lupus erythematosis, scleroderma, sepsis, rhinitis, anaphylaxis, diabetes, multiple sclerosis, graft rejection, graft vs. host disease, asthma, chronic obstructive pulmonary disease, inflammatory bowel disease, arthritis, and ischemic reperfusion injury, conditions associated with extensive trauma, or chronic inflammation, systematic inflammatory response syndrome, and multiple organ failure. 
Protutijelo ili njegov vežući fragment za uporabu prema zahtjevu 1, naznačen/o time, da je upalno ili trombotičko stanje 1li poremećaj najmanje jedno/jedan ili više odabranih iz skupine koju čine: kriza bolova vazookluzivne srpaste stanice, tromboza, ateroskleroza, tumorske metastaze, elergijske reakcije, tiroiditis, psorijaza, dermatitis, nefritis, lupus eritematoza, skleroderma, sepsa, rinitis, anafilaksa, dijabetes, multipla skleroza, odbijanje alogenskog presatka, bolest - presadak protiv domaćina, astma, kronična opstrukcijska plućna bolest, upalna bolest crijeva, artritis 1 ishemijska reperfuzijska ozljeda, stanja povezana s ekstenzivnom traumom ili kronično zapaljenje, sindrom sustavne upalne reakcije te sindrom višestrukog zastoja organa.
), and the aqueous phase was extracted with ethyl acetate. 
), i vodena faza se ekstrahira s etil acetatom.
The composition of claim 22, comprising at least 20 moles of the boronic ester compound of formula (I). 
Kompozicija prema patentnom zahtjevu 22, koja sadrži najmanje 20 mola spoja estera organoborne kiseline formule (7).
Petition: the identification number of the petition. 
(97) Broj objave europskog patenta: